160
Participants
Start Date
July 27, 2018
Primary Completion Date
October 31, 2025
Study Completion Date
December 1, 2025
ASTX727 LD
oral decitabine (LD) + cedazuridine (E7727)
ASTX727 SD
oral decitabine (SD) + cedazuridine (E7727)
Roswell Park Comprehensive Cancer Center, Buffalo
The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division), Bethesda
Mayo Clinic Florida, Jacksonville
BRCR Medical Center Inc., Plantation
Moffitt Cancer Center Site#507, Tampa
The University of Alabama at Birmingham, Birmingham
Sarah Cannon Research Institute, Nashville
Vanderbilt University Medical Center - Hematology-Oncology, Nashville
Hospital Univeristario y Politecnico La Fe Servicio de Hematologia, Valencia
Indiana University Health Hospital - Simon Cancer Center, Indianapolis
Mayo Clinic, Rochester
The University of Chicago, Chicago
University of Kansas Clinical Research Center, Westwood
University of Nebraska Medical Center, Omaha
Texas Oncology - Tyler, Tyler
The University of Texas MD Anderson Cancer Center, Houston
Universitaetsklinikum Freiburg Site#703, Freiburg im Breisgau
University of Colorado, Anschutz Cancer Pavilion, Aurora
Oregon Health and Science University Knight Cancer Institute, Portland
Yale Cancer Center, New Haven
ZNA - Campus Middelheim, Antwerp
Az St-Jan Brugge-Oostende A.V., Bruges
Universita degli Studi di Firenze, Florence
Hospital Universitario Vall d Hebron, Barcelona
Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Barcelona
Hospital General Universitario Gregorio Marañón, Madrid
London Regional Cancer Center, London
University of Alberta Hospital - Hematology Research, Edmonton
Universitätsklinikum Halle, Halle
Taiho Oncology, Inc.
INDUSTRY